Login / Signup

The association of COMT genotype with buproprion treatment response in the treatment of major depressive disorder.

Jay FawverMindy FlanaganThomas SmithMichelle DrouinMichael Mirro
Published in: Brain and behavior (2020)
High-dose bupropion is beneficial for MDD patients with Met/Val or Val/Val COMT genotypes, but not for patients with Met/Met genotype. Prospective studies are necessary to replicate this pharmacodynamic relationship between bupropion and COMT genotypes and explore economic and clinical outcomes.
Keyphrases
  • major depressive disorder
  • high dose
  • bipolar disorder
  • tyrosine kinase
  • low dose
  • stem cell transplantation
  • replacement therapy